West Pharmaceutical: A High-Quality Beat-And-Raise With More Upside Ahead

West Pharmaceutical Services delivered a beat-and-raise 1Q26, with adjusted EPS of $2.13 and revenue of $844.9M, both well ahead of expectations. WST's growth is driven by robust demand for High-Value Product components, biologics, and a favorable mix shift, supporting margin expansion and durable earnings momentum. Management raised FY26 guidance to $3.35B revenue and $8.75 adjusted EPS, reflecting operational strength but maintaining a conservative outlook amid macro uncertainties.